老年特应性皮炎

doi:10.35541/cjd.20200655

摘要/Abstract

摘要： 【摘要】近年国内外指南更新了特应性皮炎（AD）类别，增加了老年AD分型。老年AD的病因与遗传、皮肤屏障功能障碍、免疫失调及生活方式有关。但多数老年AD患者临床症状不典型，误诊十分常见。充分认识老年AD的发病机制和临床特征，根据老年AD临床特点制定个体化的诊疗方案，对改善患者生活质量，减轻疾病负担显得尤为重要。

关键词: 皮炎, 特应性, 老年人, 治疗, 临床特征

Abstract: 【Abstract】 In recent years, the category of atopic dermatitis （AD） has been updated in domestic and foreign guidelines, and elderly AD has been added as a subtype. The pathogenesis of elderly AD is related to heredity, skin barrier dysfunction, immune dysregulation and lifestyle. Most elderly AD patients have atypical clinical symptoms, and misdiagnosis is very common. To fully understand the pathogenesis and clinical characteristics of elderly AD, and to formulate individualized diagnosis and treatment plans based on clinical characteristics, are particularly important for improving the quality of life of patients and reducing the burden of the disease.

Key words: Dermatitis, atopic, Aged, Therapy, Clinical features

张锡宝董良娇叶瑞贤刘焕颜熊绮颖. 老年特应性皮炎[J]. 中华皮肤科杂志, 2021, 54(5): 447-451.doi:10.35541/cjd.20200655

Zhang Xibao, Dong Liangjiao, Ye Ruixian, Liu Huanyan, Xiong Qiying. Atopic dermatitis in the elderly[J]. Chinese Journal of Dermatology, 2021, 54(5): 447-451.doi:10.35541/cjd.20200655

参考文献 33

［1］	Nutten S. Atopic dermatitis: global epidemiology and risk factors［J］. Ann Nutr Metab, 2015,66 Suppl 1:8⁃16. doi: 10.1159/000370220.
［2］	Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey［J］. Allergy, 2018,73（6）:1284⁃1293. doi: 10.1111/all.13401.
［3］	Ha J, Lee SW, Yon DK. Ten⁃year trends and prevalence of asthma, allergic rhinitis, and atopic dermatitis among the Korean population, 2008⁃2017［J］. Clin Exp Pediatr, 2020,63（7）:278⁃283. doi: 10.3345/cep.2019.01291.
［4］	Tanei R, Hasegawa Y. Atopic dermatitis in older adults: a viewpoint from geriatric dermatology［J］. Geriatr Gerontol Int, 2016,16 Suppl 1:75⁃86. doi: 10.1111/ggi.12771.
［5］	中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000.
［6］	Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks［J］. Br J Dermatol, 2020,182（1）:47⁃54. doi: 10.1111/bjd.17896.
［7］	Shoormasti RS, Sabetkish N, Kazemnejad A, et al. Are the most common food allergens in an Iranian atopic population compatible with worldwide reports? A systemic review and meta⁃analysis with molecular classification of frequent allergens［J］. Allergol Immunopathol （Madr）, 2019,47（6）:604⁃618. doi: 10. 1016/j.aller.2019.04.005.
［8］	Chello C, Carnicelli G, Sernicola A, et al. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature［J］. Int J Dermatol, 2020,59（6）:716⁃721. doi: 10.1111/ijd.14891.
［9］	Scala E, Abeni D, Guerra EC, et al. β⁃1,3⁃glucanase rOle e 9 and MnSOD rAsp f 6 IgE reactivity are the signature of atopic dermatitis in the Mediterranean area［J］. Clin Exp Allergy, 2020,50（4）:487⁃498. doi: 10.1111/cea.13555.
［10］	Nomura T, Honda T, Kabashima K. Multipolarity of cytokine axes in the pathogenesis of atopic dermatitis in terms of age, race, species, disease stage and biomarkers［J］. Int Immunol, 2018,30（9）:419⁃428. doi: 10.1093/intimm/dxy015.
［11］	Wang S, Zhu R, Gu C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China［J］. J Eur Acad Dermatol Venereol, 2020,34（10）:2346⁃2352. doi: 10.1111/ jdv.16346.
［12］	Zhou L, Leonard A, Pavel AB, et al. Age⁃specific changes in the molecular phenotype of patients with moderate⁃to⁃severe atopic dermatitis［J］. J Allergy Clin Immunol, 2019,144（1）:144⁃156. doi: 10.1016/j.jaci.2019.01.015.
［13］	Dezoteux F, Astrid B, Chuffard M, et al. Atopic dermatitis in elderly adults［J］. Eur J Dermatol, 2019,29（4）:371⁃374. doi: 10. 1684/ejd.2019.3609.
［14］	Baum S, Porat S, Lyakhovitsky A, et al. Adult atopic dermatitis in hospitalized patients: comparison between those with childhood⁃onset and late⁃onset disease［J］. Dermatology, 2019,235（5）:365⁃371. doi: 10.1159/000499708.
［15］	Shaheen MS, Silverberg JI. Atopic dermatitis is associated with osteoporosis and osteopenia in older adults［J］. J Am Acad Dermatol, 2019,80（2）:550⁃551. doi: 10.1016/j.jaad.2018.05.026.
［16］	He H, Li R, Choi S, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2020,124（1）:70⁃78. doi: 10.1016/j.anai.2019.10.013.
［17］	Ahn HJ, Shin MK, Seo JK, et al. Cross⁃sectional study of psychiatric comorbidities in patients with atopic dermatitis and nonatopic eczema, urticaria, and psoriasis［J］. Neuropsychiatr Dis Treat, 2019,15:1469⁃1478. doi: 10.2147/NDT.S191509.
［18］	Tanei R. Atopic dermatitis in older adults: a review of treatment options［J］. Drugs Aging, 2020,37（3）:149⁃160. doi: 10.1007/s40266⁃020⁃00750⁃5.
［19］	Angelova⁃Fischer I, Rippke F, Richter D, et al. Stand⁃alone emollient treatment reduces flares after discontinuation of topical steroid treatment in atopic dermatitis: a double⁃blind, randomized, vehicle⁃controlled, left⁃right comparison study［J］. Acta Derm Venereol, 2018,98（5）:517⁃523. doi: 10.2340/00015 555⁃2882.
［20］	Chang A, Chen SC, Osterberg L, et al. A daily skincare regimen with a unique ceramide and filaggrin formulation rapidly improves chronic xerosis, pruritus, and quality of life in older adults［J］. Geriatr Nurs, 2018,39（1）:24⁃28. doi: 10.1016/j.gerinurse.2017.05.002.
［21］	Howell AN, Ghamrawi RI, Strowd LC, et al. Pharmacological management of atopic dermatitis in the elderly［J］. Expert Opin Pharmacother, 2020,21（7）:761⁃771. doi: 10.1080/14656566. 2020.1729738.
［22］	Jaworek A, Szafraniec K, Pastuszczak M, et al. The knowledge of issues associated with topical corticosteroids using in patients with atopic dermatitis［J］. Pol Merkur Lekarski, 2019,46（276）:243⁃247.
［23］	Cao T, Tey HL, Yosipovitch G. Chronic pruritus in the Geriatric population［J］. Dermatol Clin, 2018,36（3）:199⁃211. doi: 10. 1016/j.det.2018.02.004.
［24］	Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 （PDE4） inhibitor for the topical treatment of atopic dermatitis （AD） in children and adults［J］. J Am Acad Dermatol, 2016,75（3）:494⁃503.e6. doi: 10.1016/j.jaad.2016.05.046.
［25］	Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents［J］. J Am Acad Dermatol, 2014,71（2）:327⁃349. doi: 10.1016/j.jaad.2014.03.030.
［26］	Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part II［J］. J Eur Acad Dermatol Venereol, 2018,32（6）:850⁃878. doi: 10.1111/jdv.14888.
［27］	Goujon C, Nicolas JF, Nosbaum A. Methotrexate in atopic eczema. Comments to: consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part II［J］. J Eur Acad Dermatol Venereol, 2019,33（4）:e154⁃e155. doi: 10.1111/jdv.15386.
［28］	Katayama I, Aihara M, Ohya Y, et al. Japanese guidelines for atopic dermatitis 2017［J］. Allergol Int, 2017,66（2）:230⁃247. doi: 10.1016/j.alit.2016.12.003.
［29］	Drucker AM, Eyerich K, de Bruin⁃Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement［J］. Br J Dermatol, 2018,178（3）:768⁃775. doi: 10.1111/bjd.15928.
［30］	Napolitano M, Fabbrocini G, Scalvenzi M, et al. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study［J］. Clin Exp Dermatol, 2020,45（7）:888⁃890. doi: 10.1111/ced.14260.
［31］	Nygaard U, Vestergaard C, Deleuran M. Emerging treatment options in atopic dermatitis: systemic therapies［J］. Dermatology, 2017,233（5）:344⁃357. doi: 10.1159/000484406.
［32］	Nezamololama N, Fieldhouse K, Metzger K, et al. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib［J］. Drugs Context, 2020,9:2020⁃8⁃5. doi: 10.7573/dic.2020⁃8⁃5.
［33］	Guttman⁃Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16⁃week results from a randomized, placebo⁃controlled trial［J］. J Allergy Clin Immunol, 2020,145（3）:877⁃884. doi: 10.1016/j.jaci.2019.11.025.

[1]	渠莉田苏惠春程波. 特应性皮炎与系统性疾病相关性的研究进展[J]. 中华皮肤科杂志, 2021, 54(5): 463-466.
[2]	中国医疗保健国际交流促进会皮肤科分会. 女阴硬化性苔藓诊疗专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 371-375.
[3]	中国医师协会皮肤科医师分会过敏性疾病专业委员会中华医学会皮肤性病学分会特应性皮炎研究中心中国医疗保健国际交流促进会皮肤科分会. 特应性皮炎瘙痒管理专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 391-396.
[4]	李妍徐薇李邻峰. 外用丁酸氢化可的松乳膏联合一种皮肤膏剂敷料治疗特应性皮炎的随机开放对照研究 [J]. 中华皮肤科杂志, 2021, 54(5): 452-455.
[5]	杨婷张考苑李子卓李旭于波窦侠. 2型固有淋巴样细胞在MC903诱导的小鼠特应性皮炎样反应中的作用[J]. 中华皮肤科杂志, 2021, 54(4): 335-341.
[6]	胡燕燕姜倩陈柳青李东升. 反射式共聚焦显微镜在海姆泊芬光动力疗法治疗紫红型鲜红斑痣疗效评估中的应用[J]. 中华皮肤科杂志, 2021, 54(4): 342-346.
[7]	中华医学会皮肤性病学分会玫瑰痤疮研究中心中国医师协会皮肤科医师分会玫瑰痤疮专业委员会. 中国玫瑰痤疮诊疗指南（2021版）[J]. 中华皮肤科杂志, 2021, 54(4): 279-288.
[8]	邓思思宋志强. 系统性接触性皮炎的临床研究进展[J]. 中华皮肤科杂志, 2021, 54(3): 270-272.
[9]	周杰宋志强. 特应性皮炎的临床表型和内表型[J]. 中华皮肤科杂志, 2021, 54(3): 259-263.
[10]	廖志锴雷铁池. 治疗性皮肤创伤诱导白癜风皮损复色的机制与临床研究进展[J]. 中华皮肤科杂志, 2021, 54(3): 267-269.
[11]	谢波尉晓冬许爱娥林福全周妙妮. 系统糖皮质激素治疗进展期白癜风的疗效及相关因素研究[J]. 中华皮肤科杂志, 2021, 54(2): 139-144.
[12]	宋志强王欢. 特应性皮炎的治疗进展：新药物、新手段、新模式[J]. 中华皮肤科杂志, 2021, 54(2): 161-164.
[13]	中国中西医结合学会皮肤性病专业委员会色素病学组. 白癜风诊疗共识（2021版）[J]. 中华皮肤科杂志, 2021, 54(2): 105-109.
[14]	中国中西医结合学会皮肤性病专业委员会色素病学组中华医学会皮肤性病学分会白癜风研究中心中国医师协会皮肤科医师分会色素病工作组. 中国黄褐斑诊疗专家共识（2021版）[J]. 中华皮肤科杂志, 2021, 54(2): 110-115.
[15]	中国医师协会皮肤科医师分会自身免疫病专业委员会. 硫唑嘌呤治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2021, 54(2): 116-121.